about
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosisMonitoring the premalignant potential of Barrett's oesophagus'.Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosisElastic scattering spectroscopy for detection of dysplasia in Barrett's esophagus.Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophagus and cardia: a randomised study.Lasers in gastroenterology.Photodynamic therapy for cancer of the pancreas.A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus.Photodynamic therapy with m-tetrahydroxyphenyl chlorin for high-grade dysplasia and early cancer in Barrett's columnar lined esophagus.How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus.Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplasia in Barrett's oesophagus.Optimal conditions for successful ablation of high-grade dysplasia in Barrett's oesophagus using aminolaevulinic acid photodynamic therapy.Elastic scattering spectroscopy for detection of cancer risk in Barrett's esophagus: experimental and clinical validation of error removal by orthogonal subtraction for increasing accuracy.Image cytometry accurately detects DNA ploidy abnormalities and predicts late relapse to high-grade dysplasia and adenocarcinoma in Barrett's oesophagus following photodynamic therapy.Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugateComparison of nuclear texture analysis and image cytometric DNA analysis for the assessment of dysplasia in Barrett's oesophagus.Multicenter, randomized, controlled trial of confocal laser endomicroscopy assessment of residual metaplasia after mucosal ablation or resection of GI neoplasia in Barrett's esophagus.Age related changes in gut physiology and nutritional status.Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry.Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis.Clonal selection and persistence in dysplastic Barrett's esophagus and intramucosal cancers after failed radiofrequency ablation.Radiofrequency ablation for early oesophageal squamous neoplasia: outcomes form United Kingdom registryEvaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study.Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus.Mass Spectrometric Analysis of Exhaled Breath for the Identification of Volatile Organic Compound Biomarkers in Esophageal and Gastric Adenocarcinoma.High resolution colonoscopy in a bowel cancer screening program improves polyp detection.Esophageal neoplasia arising from subsquamous buried glands after an apparently successful photodynamic therapy or radiofrequency ablation for Barrett's associated neoplasia.Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registryGenetic Complexity of Crohn's Disease in Two Large Ashkenazi Jewish Families.A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy.Role of body composition and metabolic profile in Barrett's oesophagus and progression to cancer.Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.Radiofrequency ablation for Barrett's dysplasia: past, present and the future?Systematic assessment with I-SCAN magnification endoscopy and acetic acid improves dysplasia detection in patients with Barrett's esophagus.Long-term durability of radiofrequency ablation for Barrett's-related neoplasia.Squamous cell carcinoma after radiofrequency ablation for Barrett's dysplasia.Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.Development of Photodynamic Antimicrobial Chemotherapy (PACT) for Clostridium difficile.Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
P50
Q24562844-329009AD-E980-4228-9F2D-90C5A14EBAE2Q28080195-E1713885-D697-40C0-8C42-3961577A00C5Q28217930-C2CE5946-F4EB-4432-8002-8BEE6E155634Q30764833-C6BE41FF-D0C4-4BDA-9F54-281C8B751D12Q30795833-A67C4F98-FFAF-45E9-AA5A-4F33EE1BB423Q30803692-1EAF4406-2A3C-4E2B-98BD-2C80BA0E4775Q31042034-3F34F865-0A62-4493-8D52-BC89D6567AD2Q31065106-1B6F13BF-C5AA-474F-A259-05416DA2E68BQ33223990-20163E33-27C7-4259-8AD3-29191E04F518Q33289885-46A80D88-DD4D-4442-87E2-906049EC450AQ33324158-A662979C-15AC-43B5-B3E7-B1298BF3C6B3Q33389930-2C40ABA7-C112-4308-B141-54CB92D16F77Q33499489-3E6329D4-2581-455A-BCB2-FB924871E1D3Q33575943-DA9633D9-AC15-4C38-BD00-81DB9E517CEEQ33648759-A4F724BC-ECB0-450D-A456-3EA19CDBF62FQ34024948-F4C4B680-44C6-447D-8343-07A101D8C875Q34322996-BB8A1A81-614D-4075-BAD9-C690B5D55A13Q34409376-51DCFAF1-E38B-4ED5-AB2F-4F3A04527F4FQ34642545-304BFE7A-4C10-4126-A09C-E7AD6E1E72A5Q34928769-59E2CC8A-02FE-44FA-9C0C-46AE4D2F25CBQ34933881-A814D2D7-59CE-432A-A396-7CF6A1CD4E9FQ35012371-951F9CF4-DA6C-4801-A820-8776310E36ECQ35027021-F79C0139-4484-4AF9-BCE1-BC968E529BB6Q35149279-4CD036AC-F51B-4AF2-86EC-3B5FAE947D2DQ35540880-EE965D95-AC29-47F7-ABCD-99009672A67CQ35545733-C09B6CB0-50DB-45AC-AFE9-324A2A5EFDD2Q35625747-2F848980-3F18-45B9-ACA0-CE659CEE16ABQ35891829-15CD01AC-742B-4789-8707-8FE5C26DA844Q36066912-1443D181-B8C5-4AC1-930A-412DF2CD57D8Q36097775-E3BEF546-613F-413E-891C-D4C0171C456FQ36538457-510D4826-A300-4753-8AFF-506449452B70Q38005810-571D7CC0-893D-4620-B76F-2F41AA46EB02Q38323804-BF310DE9-488D-41AF-90B5-F37E3C53284CQ38367720-A6CDA686-4A78-4163-91F3-D37D42B62116Q38369561-B6759903-D029-49A0-BA15-8BE182E4E87BQ38514617-712DCC2F-70B5-40FA-9C07-BD581084FCF9Q38803427-6EDA1B5E-E58E-4F2A-8223-0816F6E102DBQ38839797-94ECEB7C-1471-4375-8983-A751A1D69EDFQ38840387-3C9F81E0-CCC4-44CB-BD68-A880BD9C355DQ40532820-58A9A523-0E29-4753-ADD5-DD9812F8A559
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Laurence B. Lovat
@ast
Laurence B. Lovat
@en
Laurence B. Lovat
@es
Laurence B. Lovat
@nl
Laurence B. Lovat
@sl
type
label
Laurence B. Lovat
@ast
Laurence B. Lovat
@en
Laurence B. Lovat
@es
Laurence B. Lovat
@nl
Laurence B. Lovat
@sl
prefLabel
Laurence B. Lovat
@ast
Laurence B. Lovat
@en
Laurence B. Lovat
@es
Laurence B. Lovat
@nl
Laurence B. Lovat
@sl
P1053
C-1986-2009
P106
P1153
57203948405
6603710340
P31
P3829
P3835
laurence-lovat
P496
0000-0003-4542-3915